JP6271510B2 - 二糖合成脂質化合物およびその使用 - Google Patents

二糖合成脂質化合物およびその使用 Download PDF

Info

Publication number
JP6271510B2
JP6271510B2 JP2015505953A JP2015505953A JP6271510B2 JP 6271510 B2 JP6271510 B2 JP 6271510B2 JP 2015505953 A JP2015505953 A JP 2015505953A JP 2015505953 A JP2015505953 A JP 2015505953A JP 6271510 B2 JP6271510 B2 JP 6271510B2
Authority
JP
Japan
Prior art keywords
compound
diglycolipid
synthetic
unsubstituted alkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512946A (ja
JP2015512946A5 (https=
Inventor
ショウ，ウォルター・エイ
バージェス，スティーブン・ダブリュ
リー，シェンロン
ヒックマン，デイビッド・ティー
ロペス−デベル，マリア・ピラール
Original Assignee
アバンティ・ポーラ・リピッド・インコーポレイテッド
エーシー イミューン エス．エー．
エーシー イミューン エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アバンティ・ポーラ・リピッド・インコーポレイテッド, エーシー イミューン エス．エー．, エーシー イミューン エス．エー． filed Critical アバンティ・ポーラ・リピッド・インコーポレイテッド
Publication of JP2015512946A publication Critical patent/JP2015512946A/ja
Publication of JP2015512946A5 publication Critical patent/JP2015512946A5/ja
Application granted granted Critical
Publication of JP6271510B2 publication Critical patent/JP6271510B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015505953A 2012-04-12 2013-04-12 二糖合成脂質化合物およびその使用 Active JP6271510B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623393P 2012-04-12 2012-04-12
US61/623,393 2012-04-12
US13/842,424 US9241988B2 (en) 2012-04-12 2013-03-15 Disaccharide synthetic lipid compounds and uses thereof
US13/842,424 2013-03-15
PCT/US2013/036425 WO2013155448A1 (en) 2012-04-12 2013-04-12 Disaccharide synthetic lipid compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017248795A Division JP6764396B2 (ja) 2012-04-12 2017-12-26 二糖合成脂質化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2015512946A JP2015512946A (ja) 2015-04-30
JP2015512946A5 JP2015512946A5 (https=) 2016-04-28
JP6271510B2 true JP6271510B2 (ja) 2018-01-31

Family

ID=49325307

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015505953A Active JP6271510B2 (ja) 2012-04-12 2013-04-12 二糖合成脂質化合物およびその使用
JP2017248795A Active JP6764396B2 (ja) 2012-04-12 2017-12-26 二糖合成脂質化合物およびその使用
JP2020091157A Active JP7189906B2 (ja) 2012-04-12 2020-05-26 二糖合成脂質化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017248795A Active JP6764396B2 (ja) 2012-04-12 2017-12-26 二糖合成脂質化合物およびその使用
JP2020091157A Active JP7189906B2 (ja) 2012-04-12 2020-05-26 二糖合成脂質化合物およびその使用

Country Status (9)

Country Link
US (2) US9241988B2 (https=)
EP (2) EP3674309B1 (https=)
JP (3) JP6271510B2 (https=)
CN (2) CN104470938B (https=)
CA (1) CA2870008C (https=)
DK (1) DK3674309T3 (https=)
ES (2) ES2787876T3 (https=)
IN (1) IN2014DN09392A (https=)
WO (1) WO2013155448A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
EP3069729A1 (en) * 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN107405395A (zh) * 2015-03-17 2017-11-28 红杉科学有限公司 疫苗与佐剂的组合物以及治疗尿路感染的方法
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
EP4590402A1 (en) 2022-09-21 2025-07-30 Wisconsin Alumni Research Foundation Compositions and methods to enhance therapeutic efficacy of cancer therapies
WO2024151642A1 (en) * 2023-01-09 2024-07-18 University Of Maryland, Baltimore Engineered anti-nociceptive-los competitive tlr4 ligands and methods for treating pain while maintaining immunosufficiency

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066794A (en) 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
JP2535048B2 (ja) 1988-02-29 1996-09-18 第一製薬株式会社 新規ジサッカライド誘導体及びその塩
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体
US5654289A (en) 1993-09-07 1997-08-05 Suntory Limited Disaccharide derivative
PL181241B1 (pl) * 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
JPH10152497A (ja) * 1996-09-30 1998-06-09 Otsuka Pharmaceut Factory Inc ヘリコバクター・ピロリのリピドａ
NZ508013A (en) * 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
EP1096954B1 (en) * 1998-07-14 2004-10-06 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid a
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
ATE518874T1 (de) * 1999-11-15 2011-08-15 Oncothyreon Inc Synthetische lipid-a analogen und verwendungen davon
CN1907289A (zh) * 2000-05-19 2007-02-07 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
HU230847B1 (en) * 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2008059307A2 (en) 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
WO2009035528A2 (en) * 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof

Also Published As

Publication number Publication date
US10143744B2 (en) 2018-12-04
JP2018070652A (ja) 2018-05-10
EP2836499B1 (en) 2020-02-26
CN107412766A (zh) 2017-12-01
IN2014DN09392A (https=) 2015-07-17
WO2013155448A1 (en) 2013-10-17
ES2787876T3 (es) 2020-10-19
JP2020147579A (ja) 2020-09-17
DK3674309T3 (da) 2024-11-25
JP7189906B2 (ja) 2022-12-14
EP3674309A1 (en) 2020-07-01
CN104470938A (zh) 2015-03-25
CA2870008A1 (en) 2013-10-17
JP6764396B2 (ja) 2020-09-30
US9241988B2 (en) 2016-01-26
US20160136271A1 (en) 2016-05-19
EP2836499A1 (en) 2015-02-18
ES2992314T3 (es) 2024-12-11
HK1207383A1 (en) 2016-01-29
CN104470938B (zh) 2017-07-28
CA2870008C (en) 2021-05-04
US20130273149A1 (en) 2013-10-17
JP2015512946A (ja) 2015-04-30
EP2836499A4 (en) 2015-11-25
EP3674309B1 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
JP7189906B2 (ja) 二糖合成脂質化合物およびその使用
US9518078B2 (en) Disaccharide synthetic lipid compounds and uses thereof
JP7386536B2 (ja) アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JPS6238330B2 (https=)
CN1997395B (zh) 含有包含在脂质体中的调节性细胞配体的药物
US4117113A (en) Immunological preparations
JP2016531853A (ja) 抗原特異的免疫原性を低減するための組成物及び方法
WO2008026781A1 (en) Reverse targeting lipid vesicle
CN118843455A (zh) 免疫原性mRNA递送媒介物
US20170349618A1 (en) Disaccharide synthetic lipid compounds and uses thereof
HK1207383B (en) Disaccharide synthetic lipid compounds and uses thereof
JP2008521871A (ja) ホスファチジルセリンおよび抗原またはアレルゲンを含む組成物、およびその使用
US20110104248A1 (en) Liposomes and immunopotentiating compositions containing the same
JP4092367B1 (ja) リポソームおよびこれを含む免疫賦活活性用組成物。
US20090306019A1 (en) Compositions for treatment of eosinophilia and related disorders
WO2025157144A1 (zh) 经黏膜给药的水包油乳液
WO2025221606A1 (en) Lipids for hyperactivation of mammalian dendritic cells
TW202342094A (zh) 高度活化之脂質奈米粒子
Gameiro et al. Pulmonary delivery of liposome-based GST1194 conformational variants: implications for vaccine development against Schistosoma mansoni infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171227

R150 Certificate of patent or registration of utility model

Ref document number: 6271510

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250